Form 4: Helix Acquisition Corp. II Executive Receives Stock Grant
Insider Transaction (Form 4)
Marc Cobo, Principal Accounting Officer of Helix Acquisition Corp. II, reported multiple transactions in common stock on September 10, 2026.
Summary
- Grant/award: acquired 9,038 Common Stock on September 10, 2026; holds 14,344 after (Direct).
- Tax/exercise-price withholding: disposed of 203 Common Stock at $5.52 ($1,121) on September 10, 2026; holds 14,141 after (Direct).
- Grant/award: acquired 43,700 Stock Option (Right to Buy) on September 10, 2026; holds 43,700 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Marc Cobo — Officer (Principal Accounting Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-10 | Grant/award | Common Stock | 9,038 | — | — | 14,344 |
| 2026-09-10 | Tax/exercise-price withholding | Common Stock | 203 | $6 | $1.1K | 14,141 |
| 2026-09-10 | Grant/award | Stock Option (Right to Buy) | 43,700 | — | — | 43,700 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-10 | Grant/award (9,038 shares) |
| 2026-09-10 | Tax/exercise-price withholding (203 shares) |
| 2026-09-10 | Grant/award (43,700 shares) |
Keywords
insider transaction, Form 4, BBOT, BridgeBio Oncology Therapeutics, Inc., neutral, Marc Cobo
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.